PDT was effectively able to treat locally solid tumors without any serious side effects. The purpose of this study was to assess the efficacy of antiangiogenic PDT using BPD-MA in nineteen dogs with head tumors. The tumor was irradiated with 690-nm laser light at 15 minutes after initiating the intravenous infusion of 0.5 mg/kg BPD-MA. In cases that were followed up for more than 1 year after PDT, the median survival time of 6 dogs with oral tumors was 423 days (range, 300-743 days) and the 1-year survival rate was 67%. In 5 dogs with nasal cavity tumors, the values were 533 days (range, 129-694 days) and 60%, respectively. The CT enhancement values before and after PDT were significantly different (p < 0.001) and were 54.3 ± 25.8 Hounsfield units (HU) (21 treatments in 15 dogs) and 5.5 ± 5.7 HU (18 treatments in 11 dogs), respectively. The mean CT enhancement value of the tumors in which 19 treatments was effective was 57.2 HU and the one for tumors in which 2 treatments was ineffective was 27.5 HU. The main side effect was temporary edema around the treated area for 1 week after PDT; however, it did not require any particular treatment. Antiangiogenic PDT is a promising method for canine solid malignant tumors without any serious side effects. Angiographic CT plays a useful role in selecting antiangiogenic PDT cases and in determining the therapeutic effect after antiangiogenic PDT. Conversely, antiangiogenic PDT using BPD-MA could be finished at short times and performed repeatedly because of BPD-MA rapid clearance and low accumulation in tissues. It is concluded that antiangiogenic PDT was effectively able to treat locally solid tumors without any serious side effects.